Drugs / rhGM-CSF
rhGM-CSF
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 26 trials | ||||||
| Phase 2 | NCT04517539 | Dec 2020 → Dec 2022 | thymic epithelial neoplasm | Shanghai Cancer Hospital, China | Unknown | No outcome recorded |
| Phase 2 | NCT03113851 | Aug 2017 → Aug 2018 | lung cancer | Peking University Cancer Hospital & Institute | Completed | No outcome recorded |
| Phase 2 | NCT02623595 | May 2016 → May 2019 | non-small cell lung carcinoma | Wuhan University | Withdrawn | No outcome recorded |
| Phase 2 | NCT02466906 | Jun 2015 → Jun 2020 | colon carcinoma | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT01806272 | Mar 2013 → Jun 2014 | nasopharyngeal carcinoma | Wei LUO | Unknown | No outcome recorded |
| Phase 2 | NCT01983657 | Jan 2012 → Jun 2014 | pulmonary alveolar proteinosis | Shanghai Pulmonary Hospital, Shanghai, China | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01785784 | Nov 2010 → Apr 2012 | — | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07305675 | Jan → Sep 2025 | — | Second Affiliated Hospital of Xi'an Jiaotong University | Completed | No outcome recorded |
| — | NCT06608303 | Oct 2024 → Mar 2025 | — | Peking University Third Hospital | Completed | No outcome recorded |
| — | NCT03489616 | Jan 2018 → Jul 2019 | non-small cell lung carcinoma | Shandong Cancer Hospital and Institute | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06552598 Background | Apr 2024 → Apr 2028 expected | cervical cancer, endometrial cancer | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT04072900 Background | Apr 2020 → Sep 2021 | cutaneous melanoma | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 1 | NCT00582140 Background | Mar 2005 → Aug 2008 | prostate cancer | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01341652 Comparator | May 2011 → Jun 2020 | prostate cancer | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2 | NCT00849121 Background | Mar 2009 → Feb 2014 | prostate cancer | University of Wisconsin, Madison | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhGM-CSF | “Human granulocyte macrophage colony-stimulating factor (rhGM-CSF), as a multifunctional haematopoietic factor, stimulates the proliferation and differentiation of...” NCT06608303 ↗14“Concurrent administration of thymalfasin and rhGM-CSF.” NCT06552598 ↗ |
| Known as | Human granulocyte macrophage colony-stimulating factor | “Human granulocyte macrophage colony-stimulating factor (rhGM-CSF), as a multifunctional haematopoietic factor, stimulates the proliferation and differentiation of...” NCT06608303 ↗ |
| Known as | recombinant human GM-CSF | “This study represents the first investigation of recombinant human GM-CSF (rhGM-CSF) gel as an adjunctive therapy following 1927-nm TFL treatment for atrophic acne scars.” NCT07305675 ↗ |
| Known as | Recombinant Human Granulocyte/Macrophage Colony-stimulating Factor | “Recombinant Human Granulocyte/Macrophage Colony-stimulating Factor Hydro-gel for Topical Application (rhGM-CSF Gel)” NCT01785784 ↗1“Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF)” NCT01806272 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Granulocyte/Macrophage Colony-stimulating Factor” NCT01785784 ↗ |
| Route | Other | “pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for 6 total doses, followed by pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. every 3 months until...” NCT00849121 ↗ |